{"nctId":"NCT00471705","briefTitle":"Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia.","startDateStruct":{"date":"2006-06"},"conditions":["Cutaneous Leishmaniasis"],"count":437,"armGroups":[{"label":"Miltefosine","type":"EXPERIMENTAL","interventionNames":["Drug: Miltefosine"]},{"label":"Glucantime®","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Glucantime®"]},{"label":"Thermotherapy","type":"EXPERIMENTAL","interventionNames":["Device: Thermotherapy"]}],"interventions":[{"name":"Miltefosine","otherNames":["Impavido®"]},{"name":"Thermotherapy","otherNames":["Thermomed"]},{"name":"Glucantime®","otherNames":["Glucantime® (meglumine antimoniate)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Parasitologically proven cases of CL based on positive smear and/or culture.\n* Patients belonging to the National Colombian Army.\n* Otherwise healthy subjects on the basis of medical history, physical examination and results of blood test (if seemed necessary by the physician)\n* Age 18-40 years.\n* Willing to participate in the study, sign the informed consent , to go to the scheduled visits and to the follow-up visits.\n* Abstain to receive any other treatment for CL during the trial and follow-up periods.\n* Non purulent lesions.\n* Mentally sane volunteers.\n* No Leishmaniasis treatment in the six months prior to the recruitment.\n* Number of lesions no more than 5\n\nExclusion criteria:\n\n* None of the lesions must be close to the anal, oral and nasal mucosa, or next to the urogenital and anal canal.\n* Serious systemic illnesses (as judged by the physician)\n* Patients with mucosal compromise.\n* Patients with diffuse Leishmaniasis ( defined as 10 or more cutaneous lesions and negative Montenegro's test)","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Complete Clinical Response","description":"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.\n\nNote: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"103","spread":null},{"groupId":"OG002","value":"86","spread":null}]}]}]},{"type":"SECONDARY","title":"Recurrence","description":"Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]}]},{"type":"PRIMARY","title":"Failure","description":"At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"42","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":145},"commonTop":["Cephalea (End of treatment)","Nausea (End of treatment )","Anorexia (End of treatment )","Myalgia (End of treatment)","Arthralgia (End of treatment)"]}}}